QQQ   426.58 (+0.17%)
AAPL   167.42 (-0.35%)
MSFT   409.31 (-0.61%)
META   509.16 (+3.03%)
GOOGL   155.85 (+0.24%)
AMZN   181.81 (+0.29%)
TSLA   150.23 (-3.36%)
NVDA   860.27 (+2.37%)
AMD   156.16 (+1.39%)
NIO   4.01 (+2.56%)
BABA   69.31 (+0.71%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   112.88 (-2.97%)
GE   156.64 (+0.62%)
CGC   7.75 (+19.41%)
DIS   113.59 (+0.58%)
AMC   2.94 (-1.34%)
PFE   25.33 (-0.35%)
PYPL   62.61 (-1.03%)
XOM   118.93 (+0.25%)
QQQ   426.58 (+0.17%)
AAPL   167.42 (-0.35%)
MSFT   409.31 (-0.61%)
META   509.16 (+3.03%)
GOOGL   155.85 (+0.24%)
AMZN   181.81 (+0.29%)
TSLA   150.23 (-3.36%)
NVDA   860.27 (+2.37%)
AMD   156.16 (+1.39%)
NIO   4.01 (+2.56%)
BABA   69.31 (+0.71%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   112.88 (-2.97%)
GE   156.64 (+0.62%)
CGC   7.75 (+19.41%)
DIS   113.59 (+0.58%)
AMC   2.94 (-1.34%)
PFE   25.33 (-0.35%)
PYPL   62.61 (-1.03%)
XOM   118.93 (+0.25%)
QQQ   426.58 (+0.17%)
AAPL   167.42 (-0.35%)
MSFT   409.31 (-0.61%)
META   509.16 (+3.03%)
GOOGL   155.85 (+0.24%)
AMZN   181.81 (+0.29%)
TSLA   150.23 (-3.36%)
NVDA   860.27 (+2.37%)
AMD   156.16 (+1.39%)
NIO   4.01 (+2.56%)
BABA   69.31 (+0.71%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   112.88 (-2.97%)
GE   156.64 (+0.62%)
CGC   7.75 (+19.41%)
DIS   113.59 (+0.58%)
AMC   2.94 (-1.34%)
PFE   25.33 (-0.35%)
PYPL   62.61 (-1.03%)
XOM   118.93 (+0.25%)
QQQ   426.58 (+0.17%)
AAPL   167.42 (-0.35%)
MSFT   409.31 (-0.61%)
META   509.16 (+3.03%)
GOOGL   155.85 (+0.24%)
AMZN   181.81 (+0.29%)
TSLA   150.23 (-3.36%)
NVDA   860.27 (+2.37%)
AMD   156.16 (+1.39%)
NIO   4.01 (+2.56%)
BABA   69.31 (+0.71%)
T   16.20 (+0.50%)
F   12.10 (+0.50%)
MU   112.88 (-2.97%)
GE   156.64 (+0.62%)
CGC   7.75 (+19.41%)
DIS   113.59 (+0.58%)
AMC   2.94 (-1.34%)
PFE   25.33 (-0.35%)
PYPL   62.61 (-1.03%)
XOM   118.93 (+0.25%)
NYSEAMERICAN:YCBD

cbdMD (YCBD) Stock Price, News & Analysis

$0.96
+0.04 (+4.35%)
(As of 12:10 PM ET)
Today's Range
$0.88
$1.04
50-Day Range
N/A
52-Week Range
$0.56
$6.75
Volume
47,284 shs
Average Volume
271,204 shs
Market Capitalization
$2.93 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

cbdMD MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
242.9% Upside
$3.00 Price Target
Short Interest
Bearish
15.79% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.96 out of 5 stars

YCBD stock logo

About cbdMD Stock (NYSEAMERICAN:YCBD)

cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. The company owns and operates consumer hemp-based CBD brands, such as cbdMD, Paw CBD, hempMD, and cbdMD Botanicals. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, drink mixes, and sleep, focus, and calming aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name; nootropic mushroom line under the ATRx brand; and hemp derived solutions under the hempMD brand. It distributes its products through its e-commerce website, third-party e-commerce sites, select distributors and marketing partners, wholesalers, and various brick and mortar retailers in the United States. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. is headquartered in Charlotte, North Carolina.

YCBD Stock Price History

YCBD Stock News Headlines

A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
A.I. Pioneer Issues Urgent Warning to Americans
According to one early A.I. pioneer: “You can either use this as an unfair advantage to grow your wealth, or you can let it ravage your retirement savings. There’s no middle option.”
cbdMD Stock (AMEX:YCBD), Guidance and Forecast
YCBD.PR.A cbdMD, Inc. 8% SER A CUM PFD
cbdMD Announces Cancellation of Special Meeting
cbdMD Announces Adjournment of Special Meeting
See More Headlines
Receive YCBD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for cbdMD and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
4/18/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Industry
Toilet preparations
Sub-Industry
N/A
Current Symbol
NYSEAMERICAN:YCBD
CIK
N/A
Fax
N/A
Employees
52
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$3.00
High Stock Price Target
$3.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+226.1%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-22,940,000.00
Pretax Margin
-87.07%

Debt

Sales & Book Value

Annual Sales
$24.16 million
Book Value
$3.16 per share

Miscellaneous

Free Float
3,016,000
Market Cap
$2.81 million
Optionable
Not Optionable
Beta
2.15
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. T. Ronan Kennedy (Age 44)
    Interim CEO, Principal Executive Officer, CFO, Secretary & Treasurer
    Comp: $275k
  • Dr. Sibyl Swift Ph.D. (Age 43)
    CSO, VP of Regulatory Affairs & Director
  • Zeb Booker
    Chief Technology Officer
  • Mr. John Weston
    Director of Investor Relations
  • Mr. Lance Blundell (Age 53)
    General Counsel
  • Robert Pettway
    Director of Public Relations
  • Mr. Francisco Mangual (Age 45)
    Senior VP of Sales
  • Ms. Shannon Charles
    Chief Marketing Officer
  • Mr. David Johnson (Age 54)
    Senior VP of Business Development

YCBD Stock Analysis - Frequently Asked Questions

Should I buy or sell cbdMD stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for cbdMD in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" YCBD shares.
View YCBD analyst ratings
or view top-rated stocks.

What is cbdMD's stock price target for 2024?

1 Wall Street analysts have issued 12 month target prices for cbdMD's shares. Their YCBD share price targets range from $3.00 to $3.00. On average, they predict the company's stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 242.9% from the stock's current price.
View analysts price targets for YCBD
or view top-rated stocks among Wall Street analysts.

Are investors shorting cbdMD?

cbdMD saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 369,400 shares, an increase of 51.3% from the March 15th total of 244,200 shares. Based on an average daily volume of 283,600 shares, the days-to-cover ratio is presently 1.3 days. Approximately 15.8% of the company's shares are short sold.
View cbdMD's Short Interest
.

How were cbdMD's earnings last quarter?

cbdMD, Inc. (NYSEAMERICAN:YCBD) posted its earnings results on Tuesday, February, 13th. The company reported ($0.67) EPS for the quarter. The firm had revenue of $5.38 million for the quarter. cbdMD had a negative trailing twelve-month return on equity of 118.28% and a negative net margin of 87.07%.

What ETF holds cbdMD's stock?

AXS Cannabis ETF holds 37,247 shares of YCBD stock, representing 0.35% of its portfolio.

When did cbdMD's stock split?

Shares of cbdMD reverse split before market open on Tuesday, April 25th 2023. The 1-45 reverse split was announced on Tuesday, April 25th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of cbdMD own?
How do I buy shares of cbdMD?

Shares of YCBD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSEAMERICAN:YCBD) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners